Research programme: anti-HIV products - AstraZeneca/Merck
Alternative Names: Anti-HIV products research programme - AstraZeneca/MerckLatest Information Update: 09 Aug 2021
At a glance
- Originator Cambridge Antibody Technology; Merck & Co
- Developer MedImmune; Merck & Co
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 28 Mar 2008 Discontinued for HIV infections in United Kingdom (unspecified route)
- 28 Mar 2008 Discontinued for HIV infections in USA (unspecified route)
- 28 Mar 2008 Discontinued for HIV infections treatment in United Kingdom (unspecified route)